is developing a novel peptide based therapeutic cancer vaccine.
The vaccine consists of a mix of peptides which are fragments of the enzyme telomerase expressed by cancer cells allowing them to divide endlessly. More than 90% of all cancer types express telomerase, making this an ideal target for a cancer vaccine. The vaccine peptides have been identified by studying long term surviving cancer patients following immunotherapy.
Clinical investigation of the novel vaccine is planned started in 2012 in collaboration with Oslo University Hospital.
Ultimovacs AS is owned by Inven2, The Norwegian Radium Hospital Research Foundation and Gjelsten Holding.
How does the vaccine work?
The goal of the vaccine is to stimulate the patient’s immune system to attack cancer cells. The therapeutic vaccine can be used on its own or in combination with conventional therapy, such as surgery, irradiation and chemotherapy.
The peptides are injected intradermally and are taken up by antigen presenting cells (dendritic cells) in the skin. Dendritic cells present the peptides to T cells in the lymph nodes and activated T cells can migrate to the tumour site where they kill the cancer cells.
The vaccine peptides should induce both killer T-cell and T helper-cell responses against telomerase and be effective across a wide variety of HLA types.
Ultimovacs AS, Gaustadalléen 21,
0349 Oslo, Norway
CEO Øyvind Kongstun Arnesen, + 47 909 71 226|